PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event
Presentation on Thursday, January 26th, 2023 at 1:30 PM EST
TARRYTOWN, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — PaxMedica, Inc. (Nasdaq:PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26th.
Related news for (PXMD)
- PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
- PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
- PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
- Threshold List Stocks with Upcoming Catalysts
- PaxMedica Meets Key PAX-101 Development Milestone and May Submit NDA